PPT-Switch to DRV/r + 3TC DUAL Study

DRVr 800100 3TC 300 QD N 126 N 123 DRVr ABC3TC or TDFFTC QD Design Randomisation 1 1 Openlabel Objective Non inferiority of DRVr 3TC at W48 HIV RNA lt 50 cmL by intention to treatexposed snapshot analysis lower margin of the 2sided 95 CI for the difference 12 80 power. r. + 3TC. OLE . Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N =. 127. N =. 123. LPV/. r. bid + 3TC/FTC . qd. Design. Randomisation*. 1: 1. Open-label. Objective. Primary Endpoint :. proportion without treatment failure at W48 . r. + RAL. HARNESS Study. ATV/. r. 300/100 mg . qd. + TDF/FTC. N = 37. N = 72. ATV/r 300/100 mg . qd. + RAL 400 mg bid. Design. Randomisation. 2 : 1. Open-label. Objective. Primary Endpoint: proportion with treatment success at W24 . Dual Switch Assembly Single Switch Assembly (11.11) 3-3/4"(95.25) (117.48) 1-1/2"(38.1) CL 800ALN Series prep (actual size shown) Compatible with all dual switch assemblies Compatible with all single Dual Switch Assembly Single Switch Assembly (11.11) 3-3/4"(95.25) (117.48) 1-1/2"(38.1) CL 800ALN Series prep (actual size shown) Compatible with all dual switch assemblies Compatible with all single Presented by. Matt Phillips. Rich Leonardo. Brief History of OhioHealth’s Infrastructure Upgrades. Current State of Infrastructure. Future Plans. Case Study Dual Bus UPS Project. NXL (transformer) vs. NX (. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . SWORD. . Study. Switch to CAB LA RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. Switch to ATV/r-. containing. . regimen. ATAZIP. Switch to ATV ± r-containing . regimen. SWAN . Study. SLOAT . Study. Switch . to ATV-. containing. . regimen. ARIES . Study. INDUMA . Study. ASSURE . Canadian Study. CHEER. Montreal Study. EASIER. SWITCHMRK. SPIRAL. Switch ER. Design. Endpoints. Primary: non inferiority in the proportion of patients with treatment failure at W48* (non completer = failure, intent-to-treat analysis), lower . Etraswitch. . Study. : Switch PI/r to ETR. Continuation of current . PI/R . + 2 . NRTI. N = . 21. N = . 22. ETR 400 mg QD* . + 2 NRTI. Design. Randomisation. 1: 1. Open-label. Objective. Primary . Endpoint: % HIV RNA < 50 c/mL, on-treatment and ITT, M=F.